OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from โ1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
OWLT
Owlet, Inc.
There isn't enough reported data to score OWLT yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OWLT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
OWLT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | โ |
| Current | 13x | $31.94 | โ |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
OWLT PE Valuation
OWLT has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
OWLT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect OWLT's losses to shrink, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus OWLT down 234%.
OWLT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.20 | -$0.82 |
| Q2 2025 | -$3.75 | -$1.14 |
| Q1 2025 | -$1.68 | +$1.82 |
| Q4 2024 | -$2.30 | +$2.23 |
| Q3 2024 | -$2.38 | +$3.57 |
| Q2 2024 | -$2.61 | +$4.88 |
| Q1 2024 | -$3.50 | +$4.34 |
| Q4 2023 | -$4.53 | +$5.41 |
OWLT is still losing money, but far less than before: $3.20 per share over the past year, against $13.28 at its worst in mid-2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over OWLT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
OWLT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $33.9M | +30% |
| Q1 2026 | $22.5M | +6.4% |
| Q4 2025 | $26.6M | +30% |
| Q3 2025 | $32M | +45% |
| Q2 2025 | $26.1M | +26% |
| Q1 2025 | $21.1M | +43% |
| Q4 2024 | $20.5M | -2.5% |
| Q3 2024 | $22.1M | +141% |
OWLT's revenue has grown year over year for six quarters in a row: $34M last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 5.1% | +13 points |
| Q1 2026 | -24% | -12 points |
| Q4 2025 | -18% | +18 points |
| Q3 2025 | 3.8% | +26 points |
| Q2 2025 | -7.4% | +3.5 points |
| Q1 2025 | -13% | +26 points |
| Q4 2024 | -36% | -22 points |
| Q3 2024 | -22% | +64 points |
OWLT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OWLT on cash generation, producing positive trailing cash flow while its opponent burns cash.
OWLT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$631K | +$1.7M |
| Q1 2026 | -$5.1M | +$865K |
| Q4 2025 | -$651K | -122% |
| Q3 2025 | -$2.2M | +$5.7M |
| Q2 2025 | -$2.3M | +$1M |
| Q1 2025 | -$5.9M | -$2.6M |
| Q4 2024 | $3M | +$4.6M |
| Q3 2024 | -$7.9M | -$2.7M |
OWLT has burned cash in almost every quarter: โ$9M over the past year, against โ$13M the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
OWLT Net Leverage
OWLT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OWLT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.1 | Neutral |
| Stochastic | 9.3 | Oversold |
OWLT's weekly RSI is 43 (neutral) and its Stochastic is 9 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OWLT PE vs Healthcare Sector
OWLT has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over OWLT on trend strength, trading above more of its moving averages.
OWLT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.49 | 2.9% above |
| 20 week MA | $5.02 | 8% below |
| 50 week MA | $7.32 | 37% below |
| 100 week MA | $6.92 | 33% below |
| 200 week MA | $5.77 | 20% below |
OWLT has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 20% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OWLT on returns for 2026, with the stronger performance.
OWLT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $135.8 | $140.8 | +3.7% |
| 2021 | $140.8 | $40.7 | -71% |
| 2022 | $40.7 | $9.57 | -77% |
| 2023 | $9.57 | $5.28 | -45% |
| 2024 | $5.28 | $4.48 | -15% |
| 2025 | $4.48 | $15.5 | +247% |
| 2026 YTD | $15.5 | $4.62 | -70% |
OWLT's yearly returns have swung widely, from +247% in 2025 to โ77% in 2022. It's down 70% so far in 2026.